Sökning: "Dermatology Life Quality Index"
Visar resultat 1 - 5 av 8 avhandlingar innehållade orden Dermatology Life Quality Index.
1. It is on my skin, on my soul, and on my life : development of a disease-specific quality of life instrument for adult patients with acute cutaneous leishmaniasis in Iran
Sammanfattning : Background: Cutaneous leishmaniasis (CL), is the most common form of a group of diseases known as leishmaniases. They are caused by obligatory intracellular protozoa from the genus Leishmania and transmitted by sandflies. LÄS MER
2. Aspects on the hand eczema and the current health care system : the possibility of health related quality of life measure as a tool for follow-up patients
Sammanfattning : Contact eczema is the most common occupational skin disease, and it predominantly affects the hands. Hand eczema is a chronic and fluctuating disease with a multidimensional impact on the patient and society, resulting in an increased consumption of health care, long term sick leave, in voluntary change of occupation, and a risk of early retirement and impaired healthrelated quality of life. LÄS MER
3. Different aspects of psoriasis etiology and treatment
Sammanfattning : Psoriasis is a chronic disease where treatments are often needed throughout life. The quality of life of patients is often affected and comorbidities are common. LÄS MER
4. Botulinum Toxin in the Treatment of Focal Hyperhidrosis and Dyshidrotic Hand Dermatitis
Sammanfattning : Excessive sweating may cause considerable disability, with psychological, social and occupational consequences. Primary hyperhidrosis may also play a key role in the pathogenesis of dyshidrotic dermatitis and some other skin diseases. LÄS MER
5. Effectiveness and costs of new medical technologies : register-based research in psoriasis
Sammanfattning : Psoriasis is a chronic, immunological and systemic disease with an estimated prevalence of about 2-3 percent. Psoriasis is associated with the joint disease psoriasis arthropathy. There are several treatments options available for psoriasis and patients with moderate to severe psoriasis generally need systemic agents. LÄS MER